CA3236237A1 - Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use - Google Patents

Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use Download PDF

Info

Publication number
CA3236237A1
CA3236237A1 CA3236237A CA3236237A CA3236237A1 CA 3236237 A1 CA3236237 A1 CA 3236237A1 CA 3236237 A CA3236237 A CA 3236237A CA 3236237 A CA3236237 A CA 3236237A CA 3236237 A1 CA3236237 A1 CA 3236237A1
Authority
CA
Canada
Prior art keywords
polypeptide
tcr
cell
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3236237A
Other languages
English (en)
French (fr)
Inventor
Cassian Yee
Ke Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3236237A1 publication Critical patent/CA3236237A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3236237A 2021-10-25 2022-10-24 Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use Pending CA3236237A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163271368P 2021-10-25 2021-10-25
US63/271,368 2021-10-25
US202163279527P 2021-11-15 2021-11-15
US63/279,527 2021-11-15
PCT/US2022/078597 WO2023076863A2 (en) 2021-10-25 2022-10-24 Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use

Publications (1)

Publication Number Publication Date
CA3236237A1 true CA3236237A1 (en) 2023-05-04

Family

ID=86158936

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3236237A Pending CA3236237A1 (en) 2021-10-25 2022-10-24 Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use

Country Status (4)

Country Link
EP (1) EP4422651A4 (https=)
JP (1) JP2024539273A (https=)
CA (1) CA3236237A1 (https=)
WO (1) WO2023076863A2 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100564T1 (it) * 2016-04-08 2022-01-10 Adaptimmune Ltd Recettori di cellule t
AU2018318303A1 (en) * 2017-08-18 2020-04-09 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
US20210061914A1 (en) * 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
BR112021025548A2 (pt) * 2019-06-18 2022-05-17 Regeneron Pharma Receptores de células t mage-a4 e métodos de uso dos mesmos
WO2021236548A1 (en) * 2020-05-18 2021-11-25 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use

Also Published As

Publication number Publication date
EP4422651A4 (en) 2025-12-17
WO2023076863A2 (en) 2023-05-04
JP2024539273A (ja) 2024-10-28
WO2023076863A3 (en) 2023-06-15
EP4422651A2 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
US20230190812A1 (en) Engineered t cell receptors and methods of use
US20240009241A1 (en) Engineered t cell receptors targeting egfr antigens and methods of use
WO2023076875A1 (en) Methods and compositions for treating glioblastoma
WO2024123975A2 (en) A t cell receptor recognizing an unmutated foxm1 epitope presented on hla-a*02:01
US20230227526A1 (en) Engineered t cell receptors and methods of use
US20230143031A1 (en) Engineered t cell receptors and methods of use
US20260007698A1 (en) Peptides and engineered t cell receptors targeting vcy antigen and methods of use
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
CA3236237A1 (en) Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
US20240009240A1 (en) Engineered t cell receptors targeting egfr antigens and methods of use
WO2025096983A1 (en) Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
WO2025101705A1 (en) Peptides and engineered t cell receptors targeting a melanoma antigen preferentially expressed in tumors antigen and methods of use
WO2026019786A1 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
EP4716699A2 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
HK40120545A (en) Engineered t cell receptors targeting egfr antigens and methods of use
WO2024123794A2 (en) A t cell receptor recognizing a her2 mutation presented on hla-a*02:01 and methods of use

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251210